University of California, San Diego Moores Cancer Center
University of California, San Diego Moores Cancer Center
La Jolla, California, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, kidney cancer, kidney disorder, neoplasm, urinary system disorder | Active, not recruiting | Phase 2 | 2026-08-12 | NCT03203473 | |
| Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma | Neoplasms by Histologic Type, basal cell carcinoma, basal cell neoplasm, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-07-28 | NCT06624475 | |
| Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Genitourinary Cancer, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, endocrine system disorder, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, penile cancer, penile disorder, penile neoplasm, small cell carcinoma | Active, not recruiting | Phase 2 | 2026-07-23 | NCT03333616 | |
| Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 | 2026-04-07 | NCT06639724 | |
| Retifanlimab and Ruxolitinib In Solid Malignancies | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-01-13 | NCT07219576 |